A global downstream medicinal cannabis opportunity

Bod Australia is a developer, distributor and marketer of health and skincare products with expertise in leveraging the health benefits associated with medicinal CBD.

Our most frequently asked question... Our service is free for investors, and we do not sell subscriptions. We search for small ASX-listed companies and profile the ones we think may have investment potential. Fortunately, some companies we profile see the value in attracting new investors and engage us to boost the visibility of their profiles - these are marked "promoted" for transparency. This allows us to maintain this website and continue doing what we love without asking you to foot the bill. Thank you for visiting and if you have any questions please do not hesitate to ask.

Company

BOD Australia Ltd
Website

bodaustralia.com
Sector

Distributors
Industry

Distributors

Code

ASX:BDA
Socials

Company Overview

Promoted

Bod Australia Limited (ASX:BDA, Bod) is a developer and distributor of natural, evidence-based health products with a focus on plant-based extracts and medicinal CBD. Bod is actively commercialising a range of over-the-counter and prescription products based on its unique, standardised, pharmaceutical-grade extracts.

The company has an extensive distribution footprint in Australia, selling a variety of prescription and OTC products to over 1,000 retail outlets, including pharmacies, retail stores and healthcare chains. Bod has also partnered with the innovation arm of the multi-billion-dollar Hong Kong listed H&H group, NewH2, to commercialise a range of OTC products using Bod's extracts. NewH2 is a recent strategic investor in Bod after investing $5.5m for a 17.64% stake in the company.

Share this profile:

Global growth potential in the downstream medicinal cannabis market.

Bod Australia is primed to accelerate sales within the new and growing $13.4bn CBD markets via its multiple strategic partnerships.

Triple-Digit Growth

Recently achieved over 860% growth in prescription volumes quarter-on-quarter, making Bod one of nation's top medicinal CBD providers.

Global Partner

Multi-billion-dollar health and wellness behemoth Health & Happiness (H&H) are a new strategic investor and partner to commercialise a range of Bod's medical products.

Research

Bod continues to collaborate with other thought leaders and is one of the five companies invited to participate in Europe’s largest medicinal cannabis project targeting 20,000 patients.

Breaking News

Bod has launched 9 hemp-based products with Swisse to enter 2,000 stores, including at Priceline, Chemist Warehouse and Coles

View Here

Introducing Medicablis

Through its partnership with Swiss Botanicals extracts manufacturer Linnea SA, Bod supplies its pharmaceutical-grade extract, MediCabilis™ 5% CBD ECs315 (MediCabilis™) via prescription. Phase 1 trials have demonstrated that Bod's oil extract and sublingual wafer have been deemed safe for human consumption showing excellent tolerability characteristics. MediCabilis™ is currently available via the Special Access Scheme (SAS-B) in the domestic market.

Latest presentation

Click here to download Bod Australia's latest presentation

View Here

Growing Sales

Prescriptions of Bod's MediCabilis™ have continued to increase as it has continued to gain wider acceptance within the medical community. Strong uptake continues through its distribution partner "Burleigh Heads Cannabis" and its partner company, "Cannabis Doctors Australia". In April 2020, repeat rpescriptions accounted for 60% of the month's total volume, with continued growth anticipated to continue.

Prescription Growth

Click here to learn more about Bod's Prescription Growth

View Here

Distribution Partners & Expansion

Bod will expand MediCabilis™ sales into the U.K. through a distribution agreement with PCCA Ltd. PCCA are an MHRA licensed medicines manufacturer with a 4,000 strong network of hospitals, physicians, clinics and medical specialists.

Learn more about PCCA

Click here to learn more about Bod Australia's exciting PCCA partnership.

View Here

Major Global Strategic Investor & Partner

NewH2, the innovation arm of multi-billion dollar Health & Happiness Group Ltd (H&H Group/HKSE:112), invested $5.5m to acquire 17.64% of Bod. H&H Group is a global leader in premium-quality adult and baby nutrition and care products listed on the Hong Kong Stock Exchange. The Group will leverage its global footprint to market and distribute H&H labelled products supplied by Bod with a near term focus on the UK, USA, France, Italy and the Netherlands. $3.9m of binding purchase orders have been received by H&H Group since October 2019. A record $1.43m purchase order was received in May 2020, the majority of going towards the company's new CBII product in partnership with H&H in the UK market.

Fully funded for aggressive growth

In addition to its $5.5m investment in Bod, $1.5m was also paid by H&H Group for the exclusive global licence to commercialise Bod’s CBD products. This arrangement has strengthened Bod's balance sheet while also allowing it to pursue an aggressive global growth agenda without significant capital outlay. Furthermore, over $1.2m was raised from the exercise of board and management options, which further strengthened Bod's balance sheet.

Read the H&H Announcement

Click here to view the H&H partnership announcement

View

Research Ongoing

Bod continues to collaborate with thought leaders in the CBD space. Bod Australia is 1 of 5 companies globally invited to participate in Project Twenty21, Europe’s largest medicinal cannabis project and will study the effects on patients with chronic conditions. Other research includes a landmark 12-month trial facilitated by "Cannabis Access Clinics" for Post Traumatic Stress Disorder (PTSD) and a collaboration with UTS to uncover a novel delivery system that can combat the skin aging process. First sales for Project21 have been achieved as of May 2020.

Project Twenty21

Click here to learn more about Europe's Project Twenty21 and Bod's involvement.

View

Strong board and management

Bod's leadership team have extensive experience working at top tier international brands. Bod also recently further strengthened its team with the appointment of Mr. Mark Masterson as its non-executive chairman. Mr Masterson held several global leadership positions across the USA, Europe, Asia and Australia during his time at global pharmaceutical behemoth Abbott Laboratories. In addition, he was the Chief Executive Officer of Australia's largest private diagnostic imaging network, I-MED, and was previously appointed as Chairman of Medicines Australia.

Information current at 12 May 2020

Company Videos

2 Videos

Interview with CommSec

Bod Australia CEO, Jo Patterson speaks with Tom Piotrowski about the company’s presence in the medicinal cannabis sector, commitment to R&D & opportunities surrounding the recent collaboration with the Health & Happiness Group.

Overview of Bod Australia

CEO Jo Patterson provides an overview of Bod Australia and its mission to be a global leader in preventative healthcare.

News Coverage

Current news mentioning BOD Australia Ltd from top publishers around the web.

Why these ASX firms are shying away from the pot stock label – Part Two

Neurotech says due to often negative publicity around cannabis companies it tends not to promote it...

Read Article

A global downstream medicinal cannabis opportunity

Company

Website

Sector

Industry

Code

Socials

Company Overview

Global growth potential in the downstream medicinal cannabis market.

Triple-Digit Growth

Global Partner

Research

Breaking News

Introducing Medicablis

Latest presentation

Growing Sales

Prescription Growth

Distribution Partners & Expansion

Learn more about PCCA

Major Global Strategic Investor & Partner

Fully funded for aggressive growth

Read the H&H Announcement

Research Ongoing

Project Twenty21

Strong board and management

Company Videos

Interview with CommSec

Overview of Bod Australia

News Coverage

Why these ASX firms are shying away from the pot stock label – Part Two

Clinical results for ancient therapy help ASX cannabis stocks weed out competition

Weed Week: Decriminalising cannabis could save Aussie tax payers billions every year

Closing Bell: It’s all about that base as metals, miners, energy inspire ASX day of action

Weed Week: More US states vote to legalise cannabis and Czech Republic to follow in Germany’s footsteps

Weed Week: Germany’s plans to legalise cannabis rekindle North American investment spark in Europe

Weed Week: The lazy stoner stereotype is a myth and this Aussie uni wants to study home grown cannabis

Weed Week: Legal use of medicinal cannabis in Australia on the rise, Lambert Initiative says

ASX Health Stocks: Big announcements as Invex and Antisense jump over 20pc this morning

Weed Week: Ice-T plans to open dispensary and Snoop Dogg’s venture capital firm backs weed snacks

Weed Week: Aurora Marijuanis and CBD bubble tea in Thailand

Weed Week: An Aussie medicinal cannabis farm for sale and crypto ATMs in weed dispensaries

Closing Bell: Small caps down, benchmark up. But the gains are all mine.

Weed Week: Cannabis lounges in Las Vegas and Cann’s Mildura cannabis facility gets GMP licence

Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour

Weed Week: Sydney Uni says it’s okay to CBD ‘n drive, and cannabis-infused drinks on the rise

Weed Week: Woody Harrelson opens weed dispensary and Byron Bay could be home to a cannabis resort

Top 10 at 10: Which ASX stocks are pumping hard today?

Weed Week: Jim Belushi headlines cannabis expo and the first legal seedbank established in Denmark

Weed Week: US seed bank launches 4/20 day NFT collection and Washington has a cannabis tax holiday

Top 10 at 10: These ASX copper, lithium and gold stocks are running their own race today

Weed Week: Wastewater doesn’t lie, Aussie cannabis consumption increased in 2021

Weed Week: New York hemp farmers get green light for cannabis crops

Weed Week: France temporarily overturns CBD ban and Canada gets a classy culinary cannabis facility

What’s the best pot stock of 2021? And who’s targeting market domination in 2022?

Weed Week: Uber Eats enters Canada’s cannabis market and Montu breaks crowdfunding records

Weed Week: Cannabis advent calendars and US Republicans introduce weed bill for veterans

Weed Week: Belushi and Aykroyd get the band back together to promote cannabis

California just passed a bill to legalise hemp – and there are ASX cannabis stocks that could benefit

Weed Week: Amazon scraps marijuana drug tests and Victorian council considers cannabis crops

These 3 ASX Healthcare shares are running hot today

Weed Week: Cannabis ice cream deal and Israeli CBD market worth US$475m by 2025

Weed Week: The CanCoin, cannabis tourism, and record medicinal product sales in Australia

ASX ends 0.6% higher; here’s what fuelled market rally

ASX trims gains on COVID-19 worries; BlueBet zooms 84% on debut

Why the Bod (ASX:BDA) share price is climbing today

BDA finishes fiscal 2021 on a high

How is ASX 200 responding to US Fed remarks?

Bod broadens UK sales footprint as CBD skincare market grows

4 ASX healthcare shares that were trending today - TLX, PIQ, BD1, BDA

Five most talked-about stocks in today’s session

Shares kick on open as BOD Australia releases double dose of good news

This ASX pathology medtech just made a substantial inroad into the UK

Why BOD Australia, Delorean shares are charging higher today

Last Orders: ASX rockets over 1 per cent led by resources; hits record closing high

3 ASX-listed healthcare stocks that are trending today – TLX, BDA, OSX

Bod Australia continues to break sales records

Up 21%, why the Bod (ASX:BDA) share price is smoking the market today

10 at 10: These ASX stocks have made their investors the most proud this morning

Bod Australia outlines strong revenue growth

Bod Australia appoints leading executive as CFO

Bod and Health & Happiness Group launch first CBD products in the UK

Bod Australia 1 of only 5 companies invited to participate in Europe's largest medicinal cannabis project